| Age of onset PsA | 45.023 | 13.2 | 44.15 | 15 | 0.507 |
| Age of onset PsO | 35.38 | 14.06 | 33.69 | 17.95 | 0.286 |
| PsA disease duration at inclusion | 8.45 | 8.74 | 8.79 | 9.99 | 0.701 |
| HLA B27 (n=112) (%) | 9.8 | | 9.8 | | >0.5 |
| BMI | 27.85 | 4.52 | 26.94 | 5.43 | 0.06 |
| Psoriasis type 1 | 165 (62.7) | | 122 (61.6) | | >0.5 |
| Numbers of DMARDS | 1.62 | 0.95 | 1.59 | 1.017 | 0.735 |
| Actual use of anti TNF | 130 (50.2) | | 74 (37.8) | | 0.008 |
| Oligo at diagnosis (%) | 93 (20.2) | | 61 (13.2) | | 0.305 |
| Poly at diagnosis (%) | 134 (29.1) | | 78 (16.9) | | 0.014 |
| Clinical articular and skin manifestations at inclusion |
| IBP (Rudwaleit criteria ≥2/4) | 76 (28.9) | | 81 (40.9) | | 0.007 |
| TJ78 | 3.71 | 6.75 | 4.55 | 7.78 | 0.215 |
| SJ76 | 2.3 | 5.19 | 1.88 | 3.31 | 0.318 |
| Number of enthesitis | 0.73 | 2.13 | 1.63 | 4.08 | 0.004 |
| Number of dactylitis | 0.35 | 1.2 | 0.2 | 0.66 | 0.114 |
| BSA | 4.87 | 11.12 | 3.03 | 6.66 | 0.074 |
| Nail involvement | 85 (32.3) | | 37 (18.9) | | 0001 |